Aug. 11, 2021
On paper, the work of University of Missouri School of Medicine researchers Haval Shirwan and Esma Yolcu appear to be at the opposite ends of the spectrum: one turns off the immune system and the other turns it up. But for Shirwan and Yolcu, professors of child health and molecular microbiology and immunology — and a husband-wife team — it all makes sense.
Through the NextGen Precision Health initiative, the duo is harnessing their diverse expertise in immunotherapy to treat diseases, such as diabetes and cancer. They will be among the first researchers to move into the NextGen Precision Health building when it opens in October.